Instructions for Authors 2019

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are used. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:

- they do not fall within the journal's policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to AR.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2019 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
8th. INTERAMERICAN ONCOLOGY CONFERENCE

CURRENT STATUS AND FUTURE OF ANTI-CANCER THERAPIES

October 17-18, 2019

FACULTY
Alex A. Adjei, Rochester, USA
Kenneth C. Anderson, Boston, USA
Stephen M. Ansell, Rochester, USA
Carlos L. Arteaga, Dallas, USA
Carlos H. Barrios, Porto Alegre, Brazil
Joaquim Bellmunt, Boston, USA
Jorge Cortés, Houston, USA
Charles Drake, NY, USA
Román Pérez-Soler, Bronx, USA
Gabriel A. Rabinovich, B. A., Argentina
Antoni Ribas, Los Angeles, USA
Josep Tabernero, Barcelona, Spain

PRELIMINARY PROGRAM
New Anticancer Therapies
Biomarkers
Immunotherapies
Melanoma
Breast Cancer
Genitourinary Cancer
Gastrointestinal Cancer
Lung Cancer
Hematological Malignancies

Universidad Católica Argentina
San José Building
Juan Pablo II Meeting Room
Puerto Madero
Buenos Aires, Argentina

www.oncologyconferences.com.ar
Selection of Recent Articles

Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. K. SATO, A. NIIDA, T. MASUDA, D. SHIMIZU, T. TOBO, Y. KURODA, H. EGUCHI, T. NAKAGAWA, Y. SUZUKI, K. MIMORI (Oita; Fukuoka; Tokyo; Chiba, Japan)

MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. U.H. WEIDLE, F. BIRZELE, A. NOPORA (Penzberg, Germany; Basel, Switzerland)

Three Poliovirus Sequences in the Human Genome Associated With Colorectal Cancer. S. LEHRER, P.H. RHEINSTEIN (New York, NY, USA)

mRNA Expression of CDK2AP1 in Human Breast Cancer: Correlation with Clinical and Pathological Parameters. R. GERA, L. MOKBEL, W.G. JIANG, K. MOKBEL (London; Cardiff, UK)

Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. S. TORKILDSEN, L. GORUNOVA, S. HEIM, G.E. TJOENNDFJORD, S. SPETALEN, B. RISBERG, H.T.T. TRAN, I. PANAGOPoulos (Oslo; Lørenskog, Norway)

Isoforms of Ionotropic Glutamate Receptor GRIK2 Induce Senescence of Carcinoma Cells. V.K. ZHAWAR, R.P. KANDPAL, R.S. ATHWAL (Philadelphia, PA; Pomona, CA, USA)

Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia. P.A. SACCA, O.N. MAZZA, C. SCORTICATI, G. VITAGLIANO, G. CASAS, J.C. CALVO (Buenos Aires, Argentina)

MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3. R. FUJII, E. OSAKA, K. SATO, Y. TOKUHASHI (Tokyo, Japan)

NOTUM Is Involved in the Progression of Colorectal Cancer. J.H. YOON, D. KIM, J. KIM, H. LEE, J. GHIM, B.J. KANG, P. SONG, S.H. RYU, T.G. LEE (Daegu; Pohang, Republic of Korea)

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. U.H. WEIDLE, A. EPP, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland)
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats. S. HIRATANI, R. MORI, Y. OTA, R. MATSUYAMA, T. KUMAMOTO, Y. NAGASHIMA, D. MROIKA, I. ENDO (Yokohama, Japan)


Cytotoxicity and Pro-inflammatory Properties of Aliphatic Alpha, Beta-unsaturated Acid and Ester Monomers in RAW264.7 Cells and Their Chemical Reactivity. Y. MURAKAMI, A. KAWATA, S. SUZUKI, S. FUJISAWA (Sakado, Japan)


Reconstruction of Spinal Soft Tissue Defects With Perforator Flaps From the Paraspinal Region. P.G. DI SUMMA, M. TREMP, A. LUNGER, F. WEIDEMANN, P. F. O’LOUGHLIN, C. KRETTEK, R. GAULKE (Hannover, Germany; Cork, Ireland)


Definitive Radiotherapy for Older Patients Aged ≥75 Years With Localized Esophageal Cancer. G. SUZUKI, H. YAMAZAKI, T. KIMOTO, D. SHIMIZU, T. NISHIMURA, A. NAKASHIMA, K. MACHIDA, K. KAWABATA, Y. OTA, H. FUJIWARA, T. ISHIKAWA, K. YAMADA (Kyoto, Japan)
Early Diagnosis of Cardiotoxicity in Patients Undergoing Chemotherapy for Acute Lymphoblastic Leukemia.
A. MILITARU, S. ZUS, A.M. CIMPEAN, S. IURCIUC, P. MATUSZ, M. IURCIUC, D. LIGHEZAN, M. MILITARU (Timisoara, Romania) ................................................................................................................................................................. 3255

Preoperative Neutrophil–lymphocyte Ratio Is a Predictor of High-output Ileostomy After Colorectal Surgery.
Y. HIRAMOTO, H. KAWAHARA, T. MATSUMOTO, M. TAKEDA, T. MISAWA, K. YANAGA (Chiba; Tokyo, Japan) .................................................................................................................................................................................. 3265


ABSTRACTS OF THE JOINT INTERNATIONAL SYMPOSIA “VITAMIN D IN PREVENTION AND THERAPY” AND “BIOLOGIC EFFECTS OF LIGHT”, 5-7 June, 2019 (Homburg/Saar, Germany) .................. 3273
Multidisciplinary Therapy for Locally Advanced Oesophageal Cancer With Special Reference to Surgical
Conversion and Salvage. M. SOHDA, T. MIYAZAKI, M. SAKAI, Y. KUMAKURA, H. HONJYO, K.
HARA, N. TANAKA, T. YOKOBORI, K. SHIRABE (Gunma, Japan) ............................................................ 3167

Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected
Pancreatic Cancer. C. TAKAGI, Y. KIKUCHI, H. SHIRAKAWA, S. HOSHIMOTO, M. TOMIKAWA, I.
OZAWA, S. HISHINUMA, Y. OGATA (Utsunomiya, Japan) ............................................................................ 3177

Preoperative Neutrophil–Lymphocyte Ratio Is a Predictor of Bowel Obstruction Due to Colorectal Cancer
Growth. S. ETO, H. KAWAHARA, T. MATSUMOTO, T. HIRABAYASHI, N. OMURA, K. YANAGA
(Saitama; Tokyo, Japan) ............................................................................................................................ 3185

Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic
Prostate Cancer. T. KOYABASHI, R. NAMITOME, Y. HIRATA, M. SHIOTA, K. IMADA, E. KASHIWAGI,
A. TAKEUCHI, J. INOKUCHI, K. TATSUGAMI, M. ETO (Fukuoka, Japan) ................................................ 3191

Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma,
Lung Adenocarcinoma and Prostatic Carcinoma. M. HU, Y. TANG, G. LONG, D. ZHANG, J.L. KRESAK,
J. LAI (Gainesville, FL; Duarte; Sacramento, CA; Rochester, NY, USA) ................................................... 3197

Intraoperative Neurological Monitoring During Neck Dissection For Esophageal Cancer With Avergent
Subclavian Artery. H. KITAGAWA, J. IWABU, K. YOKUBO, T. NAMIKA, K. HANAZAKI (Nankoku,
Japan) ..................................................................................................................................................................... 3203

Thoracoscopic Oesophagectomy Using Prone Positioning for Oesophageal Cancer With Right Aortic Arch:
A Case Report. M. GOTO, H. OKITSU, Y. YUASA, S. KURAMOTO, A. TOMIBAYASHI, D.
MATSUMOTO, O. MORI, R. TANI, H. EDAGAWA, Y. MATSUO (Tokushima; Shimane; Shiga; Kanagawa,
Japan)..................................................................................................................................................................... 3207

Gastric Emptying Improved Significantly After PRG Compared to Billroth-I Reconstruction: Assessment of
Gastric Emptying With a 13C-Breath Test. T. TAKI, Y. HOYA, K. NAKADA, M. KAWAMURA, T.
IWASAKI, K. MURAKAMI, T. OKAMOTO, N. MITSUMORI, K. YANAGA (Tokyo, Japan) ............................. 3213

Minimally Invasive Circumferential Hiatal Dissection for the Treatment of Adenocarcinoma of the Distal
Esophagus and Esophago-gastric Junction: Technical Considerations Combined With Histopathological
Outcomes. B. LORENZI, S. DAVAKIS, A. SYLLAIOS, A. KORDZADEH, M. KADRI, M. RAM, K.
FAREED, C. BARTER, A. CHARALABOPOULOS (Chelmsford; Derby, UK) .................................................... 3219

Immunohistochemical Biomarkers of Survival in Patients With Adenocarcinoma of the Uterine Cervix
Receiving Chemoradiotherapy. Y.-C. LIN, R.-Y. CHEN, J.-A. LIANG, Y.-C. HUNG, L.-S. YEH, W.-C.
CHANG, W.-C. LIN, Y.-Y. CHANG, S.-W. CHEN (Taichung; Taipei, Taiwan, ROC) ........................................ 3231

The Role of DNA Repair Glycosylase OGG1 in Intrahepatic Cholangiocarcinoma. K. SAKATA, T.
YOSHIZUMI, T. IWUMI, M. SHIMOKAWA, S. ITOH, T. IKEGAMI, N. HARADA, T. TOSHIMA, Y.
MANO, M. MORI (Fukuoka, Japan) .................................................................................................................. 3241

The Significance of Pregnancy-associated Plasma Protein A Serum Concentration in Clear Cell Renal Cell
Carcinoma. M. CECHOVA, M. CHOCHOLATY, T. ZIMA, M. BABJUK, M. KALOUSOVA (Prague, Czech
Republic) ............................................................................................................................................................ 3249

Contents continued on the preceding page
Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients. T. MIKOSHIBA, H. OZAWA, S. SAITO, Y. IKARI, N. NAKAHARA, F. ITO, Y. WATANABE, M. SEKIMIZU, Y. IMANISHI, K. OGAWA (Tokyo; Kawasaki, Japan) ................................................................. 3059

An Adult Patient With Rare Primary Intracranial Alveolar Rhabdomyosarcoma. K.B. DESAI, D. MELLA, E. PAN (Cleveland, OH; Dallas, TX, USA) ........................................................................................................ 3067

Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients With Colorectal Cancer Liver Metastases. M. MOKKARALA, C. NODA, C. MALONE, R. RAMASWAMY, O. AKINWANDE (St. Louis, MO, USA) ................................................................................ 3071

The Link Between Local Recurrence and Distant Metastases in Patients With Rectal Cancer. T. JUNGINGER, U. GOENNER, T.T. TRINH, A. HEINTZ, A. LOLLERT, M. BLETTNER, D. WOLLSCHLAEGER (Mainz, Germany) .................................................................................................................................................................. 3079

Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer. T. ITO, K. KANAO, K. TAKAHARA, R. ANDO, T. YASUI, R. SHIROKI, M. SUMITOMO, H. MIYAKE (Hamamatsu; Nagakute; Toyoake; Nagoya, Japan) ........................................................................................................................................................................ 3089

Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. S. BISELLO, M. BUWENGE, A. PALLONI, R. AUTORINO, F. CELLINI, G. MACCHIA, F. DEODATO, S. CILLA, G. BRANDI, L. TAGLIAFERRI, S. CAMMELLI, V. VALENTINI, A.G. MORGANTI, G.C. MATTIUCCI (Bologna; Rome; Campobasso, Italy) ........................................................................................................................................................................ 3095

Multiparametric MRI Versus Multiparametric US in the Detection of Prostate Cancer. F.M. DRUDI, V. CANTISANI, F. ANGELINI, M. CICCARIELLO, D. MESSINEO, E. ETTORRE, M. LIBERATORE, M. SCIALPI (Rome; Perugia, Italy) ........................................................................................................................................................................... 3101


Comprehensive Analysis of Red Blood Cell Distribution Width as a Preoperative Prognostic Predictor in Gastric Cancer. N. HIRAHARA, Y. TAJIMA, Y. FUJII, S. KAJI, T. YAMAMOTO, R. HYAKUDOMI, T. TANIURA, Y. KAWABATA (Izumo, Japan) ........................................................................................................................................................................... 3121


Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States. W. HAQUE, V. VERMA, E.B. BUTLER, B.S. TEH (Houston, TX; Pittsburgh, PA, USA) ........................................................................................................................................................................... 3137


Clinical Outcomes of Isolated Regional Lymph Node Recurrence in Patients With Malignant Cutaneous Melanoma. J. KWON, Y.A. KIM, C. LEE, B.H. KIM, S. KIM, I.H. KIM (Daejeon; Seoul, Republic of Korea) ........................................................................................................................................................................... 3147

Psychosocial Distress in Follow-up Care – Results of a Tablet-based Routine Screening in 202 Patients With Sarcoma. F. LENZE, F. POHLLIG, C. KNEBEL, H. MÜHLHOFER, H. RECHL, T. PICHLER, P. HERSCHBACH, R. VON EISENHART-ROTHE, U. LENZE (Munich, Germany) ........................................................................................................................................................................... 3159
A Rare Case of Distal Interphalangeal Chondromatosis in the Middle Finger: Case Report With Review of Literature. L. SENESI, P.P. PANGRAZI, A. MARCHESINI, F. DE FRANCESCO, A. GIORDANO, A. GIGANTE, M. RICCIO (Ancona, Italy; Philadelphia, PA, USA) ........................................................................................................................................... 2951

Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumor After Resection of Lung Cancer. S. TAKAHASHI, T. GO, M. ANADA, T. KINOSHITA, T. NISHIDE, H. YOKOMISE, T. SHIBATA (Kagawa, Japan) ................................................................................................................................ 2957

MRI in the Follow-up of Testicular Cancer: Less is More. E. RUD, C.W. LANGBERG, E. BACO, P. LAURITZEN, G. SANDBÆK (Oslo, Norway) ..................................................................................................................................................... 2963


Anastomotic Leakage in Rectal Surgery: Role of the Ghost Ileostomy. P. PALUMBO, S. USAI, A. PANSA, S. LUCCHESE, R. CARONNA, S. BONA (Rome; Rozzano, Italy) .................................................................................................................. 2975


Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies. Z. EL ALI, S. ROTTEY, P. BARTHELEMY, N. KOTECKI, R. VAN PAEMEL, D. DEVRIENT, A. AWADA, T. GIL, D. PANNIER, T. RYCKEWAERT, W. WAISSE, J.-B. CLAVER, N. PENEL, T. VERMASSEN (Brussels; Ghent, Belgium; Strasbourg; Lille, France) .............................................................................................................................................. 2993


Effectiveness of Image-guided Brachytherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy. S.-W. CHEN, J.-A. LIANG, Y.-C. HUN, L.-S. YEH, W.-C. CHANG, W.-C. LIN, Y.-Y. CHANG (Taichung; Taipei, Taiwan, ROC) .......................................................................................................................................................... 3015

Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection. T. LEE, C.-K. PARK, S.Y. HA (Seoul, Republic of Korea) .......................................................................................................................................................... 3025


Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma. H. TAKAHASHI, K. SAKAKURA, Y. ARISAKA, A. TOKIE, K. KAIRA, H. TADA, T. HIGUCHI, A. OKAMOTO, Y. TSUSHIMA, K. CHIKAMATSU (Maebashi; Hidaka, Japan) .................................................................................................................................................. 3039

Reevaluation of Preoperative Chemoradiotherapy for Clinical T3 Lower Rectal Cancer: A Multicenter Collaborative Retrospective Clinical Study. M. TAKEDA, H. KAWAHARA, M. OGAWA, K. SUWA, K. ETO, K. YANAGA (Chiba; Tokyo, Japan) .................................................................................................................................................. 3047


Contents continued on the preceding page

The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer. D. ISHIKAWA, C. TAKASU, H. KASHIHARA, M. NISHI, T. TOKUNAGA, J. HIGASHIJIMA, K. YOSHIKAWA, K. YASUTOMO, M. SHIMADA (Tokushima, Japan) ................................................................. 2855


Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma. Y.Y. JUNG, H.Y. WOO, H.-S. KIM (Goyang; Seoul, Republic of Korea) ....................................................................................................................................... 2883


Clinical Studies


Should we Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer? M. GOSSET, C. CHARGARI, E. BENTIVEGNA, A. LEARY, C. GENESTIE, A. MAULARD, P. MORICE, S. GOUY (Villejuif Cedex; Kremlin Bicêtre, France) ............................................ 2919

RAND-36-Item Health Survey: A Comprehensive Test for Long-term Outcome and Health Status Following Surgery. I. SAIMANEN, V. KUOSMANEN, D. RAHKOLA, T. SELANDER, J. KÄRKKÄINEN, J. HARJU, S. ASPINEN, M. ESKELINEN (Kuopio; Helsinki, Finland) ................................................................................................................................. 2927


Contents continued on the preceding page
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma. C. LIU, Y.-H. JIANG, Z.-L. ZHAO, H.-W. WU, L. ZHANG, Z. YANG, R.M. HOFFMAN, J.-W. ZHENG (Shanghai; Shandong; Nanjing, PR China; San Diego, CA, USA) .... 2729


Regulation of Differentiation of HC11 Mouse Breast Epithelial Cells by the Signal Transducer and Activator of Transcription-3. M. NIIT, M. GELETU, Z. TAHA, R. ARULANANDAM, J. CASS, V. HOSKIN, B. ELLIOTT, P. GUNNING, L. RAPTIS (Kingston; Mississauga; Ottawa, ON, Canada) ........................................... 2749


CD204-Positive Tumor-associated Macrophages Relate to Malignant Transformation of Colorectal Adenoma. D. TANIYAMA, K. TANIYAMA, K. KURAH, H. YAMAMOTO, J. ZAITSU, A. SAIJO, N. SAKAMOTO, K. SENTANI, N. OUE, W. YASUI (Hirosima; Kure, Japan) ............................................................................................................................ 2767

Postoperative Inflammation Is an Independent Prognostic Factor in Patients With Thoracic Esophageal Squamous Cell Carcinoma. T. TOYOKAWA, T. TAMURA, K. SAKURAI, N. KUBO, H. TANAKA, K. MUGURUMA, M. YASHIRO, M. OHIRA (Osaka, Japan) ........................................................................ 2777

FOXII Immunohistochemistry Differentiates Benign Renal Oncocytoma from Malignant Chromophobe Renal Cell Carcinoma. A. MOLNAR, C.A. HORVATH, P. CZOVEK, A. SZANTO, G. KOVACS (Pecs, Hungary; Heidelberg, Germany) ......................................................... 2785


Feasibility of a Tungsten Rubber Grid Collimator for Electron Grid Therapy. K. KIJIIMA, A. KRISANACHINDA, M. TAMURA, Y. NISHIMURA, H. MONZEN (Osaka, Japan; Bangkok, Thailand) ......................................... 2799

Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report. Z. MICHALOVÁ, M. ČOMA, M. KIČOVÁ, J. GABZDILOVÁ, K. DEDINSKÁ, T. GUMAN, M. HÁJIKOVÁ, D. VESELINYOVÁ, M. GIERTLOVA, P. GÁL, M. ŠARIŠSKÝ (Kosice, Slovak Republic; Prague, Czech Republic) ......................................................................................................................... 2805

IGF-IIEc Expression Is Associated With Advanced Differentiated Thyroid Cancer. A.K. KARAGIANNIS, A. PHILIPPOU, S. TSELENI-BALAFOUTA, E. ZEVOLIS, T. NAKOUTI, M. TSOPANOMICHALOU-GKLOTSSOU, V. PSARRAS, M. KOUTSILLIEN (Athens; Thessaloniki, Greece; Singapore, Singapore) .... 2811

The Triple-negative Breast Cancer Cell Line MDA-MB 231 Is Specifically Inhibited by the Ionophore Salinomycin. T. HERO, H. BÜHLER, P. NGUEMGO KOUM, B. PRIESCH-GRZESZOWIAK, T. LATEIT, I.A. ADAMIETZ (Herne, Germany) ........................................................................................................ 2821

IGFBP1 Is a Predictive Factor for Haematogenous Metastasis in Patients With Gastric Cancer. Y. SATO, M. INOKUCHI, Y. TAKAGI, K. KOJIMA (Tokyo; Tochigi, Japan) .................................................................................. 2829

Dosimetric Characterization of a Novel Surface Collimator With Tungsten Functional Paper for Electron Therapy. Y. KAWAI, M. TAMURA, M. AMANO, T. KAMOMAE, H. MONZEN (Shizuoka; Osaka; Aichi, Japan) ........................................................................................................ 2839

Contents continued on the preceding page